Thrombocytopenia - Epidemiology Forecast - 2032

Thrombocytopenia Understanding

Thrombocytopenia Overview

Thrombocytopenia Understanding

Thrombocytopenia Overview

• Thrombocytopenia has many etiologies, such as bone marrow failure, bone marrow suppression (e.g., from medication, chemotherapy, or irradiation), chronic alcohol abuse, myelodysplastic syndrome, autoimmune syndromes, etc.

Thrombocytopenia Indications

• Immune thrombocytopenic purpura (ITP): An acquired immune-mediated disorder characterized by isolated thrombocytopenia and the absence of other conditions or agents known to induce thrombocytopenia. The incidence is 100 cases per 1 million persons annually, and approximately 50% of cases occur in children. Immune thrombocytopenic purpura in children often resolves spontaneously but is more insidious and chronic in adults. The risk of bleeding correlates to the severity of thrombocytopenia. Patients may present without symptoms, minimal bleeding, or serious hemorrhage (e.g., mucosal, intracranial, gastrointestinal, genitourinary). Older patients, patients on antiplatelet therapy, and patients with comorbid conditions may have severe bleeding manifestations.
• Drug-induced thrombocytopenia: One of the most common types of thrombocytopenia in the outpatient setting is drug-induced thrombocytopenia. An epidemiologic study from Europe and the US showed an annual incidence of 10 cases/1 million persons, but numbers could be higher in older and hospitalized patients. Drug-induced thrombocytopenia is suspected in all patients presenting with an acute drop in platelet count. Most patients with drug-induced thrombocytopenia have moderate-to-severe thrombocytopenia reaching a nadir platelet count of 20 × 103/μL. During treatment, physicians should ask specific questions about the use of any medications, including nutritional supplements and over-the-counter remedies being taken by the patient. Quinine is a common cause of drug-induced thrombocytopenia and is often missed in the patient's history.

Thrombocytopenia Epidemiology

Thrombocytopenia Detailed Epidemiology Segmentation

Key Findings

• In 2021, the total cases of Thrombocytopenia in the 7MM countries were 2,608,095, and these cases are anticipated to increase during the study period. The US accounted for 1,045,247 cases of Thrombocytopenia in 2021.
• Among the European countries, Germany had the highest number of cases of Thrombocytopenia in 2021, i.e., 453,441 cases, followed by the UK which had 269,422 cases in 2021. On the other hand, Italy had the lowest number of cases of Thrombocytopenia, i.e. 127,166 cases in 2021.
• The highest cases of TTP were seen in US which accounted for 6,002 cases in 2021.
• Japan, in 2021, accounted for 58,261 cases of Chemotherapy-induced Thrombocytopenia, which is expected to increase during the study period.
• The maximum number of cases of Heparin-induced Thrombocytopenia in 2021 were recorded in Germany out of all the EU-5 countries and Spain accounted for the least number of cases.

Scope of the Report

• The report covers a descriptive overview of Thrombocytopenia, explaining its procedure, types, indications, and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the Thrombocytopenia risk and burden.
• The report provides the segmentation of the epidemiology for 7MM by segmented by ‘Total Cases of Thrombocytopenic Purpura (TTP), Total Cases of Immune Thrombocytopenia (ITP), Total Cases of Thrombocytopenia in Chronic Liver Disease, Total Cases of Chemotherapy-induced Thrombocytopenia, Total Number of Cases of Heparin-induced Thrombocytopenia, and Total Cases of Thrombocytopenia'.

Report Highlights

• 11-Year Forecast of Thrombocytopenia
• 7MM Coverage
• Total Cases of Thrombocytopenia Molecular Alteration- Type-specific Cases of Thrombocytopenia
• Total Cases of Thrombocytopenia by Indication

Key Questions Answered

• What are the risk, burdens, and unmet needs of Thrombocytopenia?
• What is the historical Thrombocytopenia patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Thrombocytopenia at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Thrombocytopenia?
• Out of the countries mentioned above, which country would have the highest cases of Thrombocytopenia during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

• Develop business strategies by understanding the trends, shaping and driving the 7MM Thrombocytopenia epidemiology.
• The Thrombocytopenia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Thrombocytopenia epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Geographies Covered

• The United States
• The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan